Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

New Research Arrangements, Investor Conference Schedules, Reimbursement Agreements, and NDA Acceptances - Research Report on



   New Research Arrangements, Investor Conference Schedules, Reimbursement
    Agreements, and NDA Acceptances - Research Report on Quintiles, Insys,
                     HeartWare, Given Imaging, and Nektar

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 28, 2013

NEW YORK, November 28, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Quintiles
Transnational Holdings Inc. (NYSE: Q), Insys Therapeutics, Inc. (NASDAQ:
INSY), HeartWare International, Inc. (NASDAQ: HTWR), Given Imaging Ltd.
(NASDAQ: GIVN), and Nektar Therapeutics (NASDAQ: NKTR). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Quintiles Transnational Holdings Inc. Research Report

On November 20, 2013, Quintiles Transnational Holdings Inc. (Quintiles)
announced that the Vietnam Ministry of Health's Administration of Science,
Technology and Training (ASTT) has signed an agreement with the Company to
enhance clinical research in Vietnam. Under the two-year agreement, the
Company informed that it will collaborate with ASTT to form a larger working
group for addressing variety of topics, including  improved processes for
trial management, development of streamlined processes to improve trial
efficiency and quality, and training for investigators and ethics committees.
"Quintiles knows how to conduct clinical research to global standards and its
experts understand Asia and Vietnam," said Prof. Nguyen Cong Khan, M.D.,
Ph.D., Director of ASTT. "By sharing their knowledge and insights, Quintiles
can help us develop and execute a long-term plan for improving the quality,
scope and breadth of clinical research in Vietnam." The Full Research Report
on Quintiles Transnational Holdings Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/9f5c_Q

--

Insys Therapeutics, Inc. Research Report

On November 20, 2013, Insys Therapeutics, Inc. (Insys) announced that it is
scheduled to present at two upcoming investor conferences: the 25th Annual
Piper Jaffray Healthcare Conference taking place on December 3-4, 2013 at The
New York Palace, and at the 24^th Annual Oppenheimer Healthcare Conference
taking place on December 10-11, 2013 at the Crowne Plaza Hotel. The Company
informed that its management is scheduled to present at the 25th Annual Piper
Jaffray Healthcare Conference on December 3, 2013 at 2:30 p.m. EST; and at the
24^th Annual Oppenheimer Healthcare Conference on December 10, 2013 at 3:55
p.m. EST. The Full Research Report on Insys Therapeutics, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/4c7f_INSY

--

HeartWare International, Inc. Research Report

On November 25, 2013, HeartWare International, Inc. (HeartWare) announced that
it will be presenting at the 25^th Annual Piper Jaffray Healthcare Conference
to be held on December 3-4, 2013 at the Palace Hotel in New York City. The
Company's CEO, Doug Godshall, is scheduled to present on December 3, 2013 at
2:00 p.m. ET. The Full Research Report on HeartWare International, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/0461_HTWR

--

Given Imaging Ltd. Research Report

On November 11, 2013, Given Imaging Ltd. (Given Imaging) announced that
Japan's Central Social Insurance Medical Council (Chuikyo) has approved the
recommendation by the Japanese Ministry of Health Labor, and Welfare (MHLW) to
provide the reimbursement for the Company's PillCam COLON. Given Imaging
stated that with this approval, Chuikyo established a reimbursement of
¥83,100, or approximately $840, per capsule, scheduled to go into effect on
January 1, 2014. "We thank the Japanese government for moving so quickly to
provide reimbursement for PillCam COLON so that more patients can have access
to a safe and effective diagnostic and screening tool for detecting diseases
of the colon," said Homi Shamir, President and CEO of Given Imaging. "We are
training our team now so that we can maximize this opportunity in 2014." The
Full Research Report on Given Imaging Ltd. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/e538_GIVN

--

Nektar Therapeutics Research Report

On November 19, 2013, Nektar Therapeutics (Nektar) reported that the US FDA
has accepted the NDA for naloxegol, an investigational peripherally-acting
mu-opioid receptor antagonist (PAMORA), which has been studied in
opioid-induced constipation (OIC) in adult patients with chronic non-cancer
pain, as announced by Astra Zeneca. The Company also informed that naloxegol
is part of the exclusive worldwide license agreement between the Company and
AstraZeneca, and was developed using the Company's oral small molecule polymer
conjugate technology. The Full Research Report on Nektar Therapeutics -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/3421_NKTR

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement